Adverse Outcome Pathways and Drug-Induced Liver Injury Testing

Chemical Research in Toxicology

Volumn 28, Issue 7, 2015, Pages 1391-1397

  Vinken, Mathieu ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CHOLESTASIS; FATTY LIVER; HUMAN; LIVER FIBROSIS; NONHUMAN; REVIEW; RISK ASSESSMENT; TOXIC HEPATITIS; TOXICITY TESTING; CHEMICALLY INDUCED; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BOSENTAN; METHOTREXATE; SULFONAMIDE; VALPROIC ACID;

CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; METHOTREXATE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; VALPROIC ACID;

EID: 84937688579     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.5b00208     Document Type: Review

References (64)

1. Przybylak, K. R. and Cronin, M. T. (2012) In silico models for drug-induced liver injury: current status Expert Opin. Drug Metab. Toxicol. 8, 201-217 10.1517/17425255.2012.648613
2. Faa, G., Ekstrom, J., Castagnola, M., Gibo, Y., Ottonello, G., and Fanos, V. (2012) A developmental approach to drug-induced liver injury in newborns and children Curr. Med. Chem. 19, 4581-4594 10.2174/092986712803306385
3. Holt, M. P. and Ju, C. (2006) Mechanisms of drug-induced liver injury AAPS J. 8, E48-E54 10.1208/aapsj080106
4. Verma, S. and Kaplowitz, N. (2009) Diagnosis, management and prevention of drug-induced liver injury Gut 58, 1555-1564 10.1136/gut.2008.163675
5. Andrade, R. J., Agundez, J. A., Lucena, M. I., Martinez, C., Cueto, R., and Garcia-Martin, E. (2009) Pharmacogenomics in drug induced liver injury Curr. Drug Metab. 10, 956-970 10.2174/138920009790711805
6. Andrade, R. J., Robles, M., Ulzurrun, E., and Lucena, M. I. (2009) Drug-induced liver injury: insights from genetic studies Pharmacogenomics 10, 1467-1487 10.2217/pgs.09.111
7. Blomme, E. A., Yang, Y., and Waring, J. F. (2009) Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development Toxicol. Lett. 186, 22-31 10.1016/j.toxlet.2008.09.017
8. Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J., and Jaeschke, H. (2010) Mechanisms of immune-mediated liver injury Toxicol. Sci. 115, 307-321 10.1093/toxsci/kfq009
9. Uetrecht, J. (2009) Immunoallergic drug-induced liver injury in humans Semin. Liver Dis. 29, 383-392 10.1055/s-0029-1240007
10. Guengerich, F. P. (2011) Mechanisms of drug toxicity and relevance to pharmaceutical development Drug Metab. Pharmacokinet. 26, 3-14 10.2133/dmpk.DMPK-10-RV-062
11. Ramachandran, R. and Kakar, S. (2009) Histological patterns in drug-induced liver disease J. Clin. Pathol. 62, 481-492 10.1136/jcp.2008.058248
12. Zimmerman, H. J. (2000) Drug-induced liver disease Clin. Liver Dis. 4, 73-96 10.1016/S1089-3261(05)70097-0
13. Tujios, S. and Fontana, R. J. (2011) Mechanisms of drug-induced liver injury: from bedside to bench Nat. Rev. Gastroenterol. Hepatol. 8, 202-211 10.1038/nrgastro.2011.22
14. Chalasani, N. and Bjornsson, E. (2010) Risk factors for idiosyncratic drug-induced liver injury Gastroenterology 138, 2246-2259 10.1053/j.gastro.2010.04.001
15. Cui, Y. and Paules, R. S. (2010) Use of transcriptomics in understanding mechanisms of drug-induced toxicity Pharmacogenomics 11, 573-585 10.2217/pgs.10.37
16. Bjornsson, E. (2010) Drug-induced liver injury in clinical practice Aliment. Pharmacol. Ther. 32, 3-13 10.1111/j.1365-2036.2010.04320.x
17. Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., Serrrano, J. A., Tietge, J. E., and Villeneuve, D. L. (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment Environ. Toxicol. Chem. 29, 730-741 10.1002/etc.34
18. Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, M. (2014) Adverse outcome pathway (AOP) development I: strategies and principles Toxicol. Sci. 142, 312-320 10.1093/toxsci/kfu199
19. Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, M. (2014) Adverse outcome pathway development II: best practices Toxicol. Sci. 142, 321-330 10.1093/toxsci/kfu200
20. Vinken, M. (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology Toxicology 312, 158-165 10.1016/j.tox.2013.08.011
21. https://aopkb.org/ (consulted Jun 2015).
22. Willett, C., Caverly Rae, J., Goyak, K. O., Landesmann, B., Minsavage, G., and Westmoreland, C. (2014) Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes ALTEX 31, 407-421 10.14573/altex.1401283
23. Willett, C., Caverly Rae, J., Goyak, K. O., Minsavage, G., Westmoreland, C., Andersen, M., Avigan, M., Duché, D., Harris, G., Hartung, T., Jaeschke, H., Kleensang, A., Landesmann, B., Martos, S., Matevia, M., Toole, C., Rowan, A., Schultz, T., Seed, J., Senior, J., Shah, I., Subramanian, K., Vinken, M., and Watkins, P. (2014) Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action ALTEX 31, 500-519 10.14573/altex.1401281
24. Lee, U. E. and Friedman, S. L. (2011) Mechanisms of hepatic fibrogenesis Best Pract. Res. Clin. Gastroenterol. 25, 195-206 10.1016/j.bpg.2011.02.005
25. Trautwein, C., Friedman, S. L., Schuppan, D., and Pinzani, M. (2015) Hepatic fibrosis: concept to treatment J. Hepatol. 62, S15-S24 10.1016/j.jhep.2015.02.039
26. Friedman, S. L. (2010) Evolving challenges in hepatic fibrosis Nat. Rev. Gastroenterol. Hepatol. 7, 425-436 10.1038/nrgastro.2010.97
27. Vinken, M., Maes, M., Vanhaecke, T., and Rogiers, V. (2013) Drug-induced liver injury: mechanisms, types and biomarkers Curr. Med. Chem. 20, 3011-3021 10.2174/0929867311320240006
28. Landesmann, B., Lostia, A., Horvat, T., Vinken, M., Munn, S., and Whelan, M. (2015) Adverse outcome pathway development from protein alkylation to liver fibrosis PLoS One, submitted.
29. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver J. Hepatol. 54, 773-794 10.1016/j.jhep.2010.11.006
30. Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2011) Human fatty liver disease: old questions and new insights Science 332, 1519-1523 10.1126/science.1204265e
31. Amacher, D. E. (2011) The mechanistic basis for the induction of hepatic steatosis by xenobiotics Expert Opin. Drug Metab. Toxicol. 7, 949-965 10.1517/17425255.2011.577740
32. Ramachandran, R. and Kakar, S. (2009) Histological patterns in drug-induced liver disease J. Clin. Pathol. 62, 481-492 10.1136/jcp.2008.058248
33. Zimmerman, H. J. (2000) Drug-induced liver disease Clin. Liver Dis. 4, 73-96 10.1016/S1089-3261(05)70097-0
34. Landesmann, B., Goumenou, M., Munn, S., and Whelan, M. (2012) Description of Prototype Modes-of-Action Related to Repeated Dose Toxicity. JRC Scientific and Policy Report, 75689, Publications Office of the European Union: Luxembourg, DOI: 10.2788/71112.
35. Oorts, M., Richert, L., and Annaert, P. (2015) Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture J. Pharmacol. Toxicol. Methods 73, 63-71 10.1016/j.vascn.2015.03.002
36. Schoemaker, M. H., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L., and Moshage, H. (2004) Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways Hepatology 39, 1563-1573 10.1002/hep.20246
37. Woolbright, B. L. and Jaeschke, H. (2012) Novel insight into mechanisms of cholestatic liver injury World J. Gastroenterol. 18, 4985-4993 10.3748/wjg.v18.i36.4985
38. Hofmann, A. F. (2009) Bile Acids and the Enterohepatic Circulation, in The Liver: Biology and Pathobiology (Arias, I. M., Alter, H. J., Boyer, J. L., Cohen, D. E., Fausto, N., Shafritz, D. A., and Wolkoff, A. W., Eds.) pp 289-304, Wiley-Blackwell, Oxford, U.K.
39. Padda, M. S., Sanchez, M., Akhtar, A. J., and Boyer, J. L. (2011) Drug-induced cholestasis Hepatology 53, 1377-1387 10.1002/hep.24229
40. Zollner, G. and Trauner, M. (2006) Molecular mechanisms of cholestasis Wien. Med. Wochenschr. 156, 380-385 10.1007/s10354-006-0312-7
41. Zollner, G. and Trauner, M. (2008) Mechanisms of cholestasis Clin. Liver Dis. 12, 1-26 10.1016/j.cld.2007.11.010
42. Wagner, M., Zollner, G., and Trauner, M. (2009) New molecular insights into the mechanisms of cholestasis J. Hepatol. 51, 565-580 10.1016/j.jhep.2009.05.012
43. Vinken, M., Landesmann, B., Goumenou, M., Vinken, S., Shah, I., Jaeschke, H., Willett, C., Whelan, M., and Rogiers, V. (2013) Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury Toxicol. Sci. 136, 97-106 10.1093/toxsci/kft177
44. Ellison, C. M., Enoch, S. J., and Cronin, M. T. (2011) A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity Expert Opin. Drug Metab. Toxicol. 7, 1481-1495 10.1517/17425255.2011.629186
45. Patlewicz, G., Simon, T. W., Rowlands, J. C., Budinsky, R. A., and Becker, R. A. (2015) Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes Regul. Toxicol. Pharmacol. 71, 463-477 10.1016/j.yrtph.2015.02.011
46. Przybylak, K. R. and Cronin, M. T. (2012) In silico models for drug-induced liver injury: current status Expert Opin. Drug Metab. Toxicol. 8, 201-217 10.1517/17425255.2012.648613
47. Hirano, H., Kurata, A., Onishi, Y., Sakurai, A., Saito, H., Nakagawa, H., Nagakura, M., Tarui, S., Kanamori, Y., Kitajima, M., and Ishikawa, T. (2006) High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis Mol. Pharmaceutics 3, 252-265 10.1021/mp060004w
48. Saito, H., Osumi, M., Hirano, H., Shin, W., Nakamura, R., and Ishikawa, T. (2009) Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP) AAPS J. 11, 581-589 10.1208/s12248-009-9137-9
49. Warner, D. J., Chen, H., Cantin, L. D., Kenna, J. G., Stahl, S., Walker, C. L., and Noeske, T. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification Drug Metab. Dispos. 40, 2332-2341 10.1124/dmd.112.047068
50. Honório, K. M., Salum, L. B., Garratt, R. C., Polikarpov, I., and Andricopulo, A. D. (2008) Two- and three-dimensional quantitative structure-activity relationships studies on a series of liver X receptor ligands Open Med. Chem. J. 2, 87-96 10.2174/1874104500802010087
51. Hewitt, M., Enoch, S. J., Madden, J. C., Przybylak, K. R., and Cronin, M. T. (2013) Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action Crit. Rev. Toxicol. 43, 537-558 10.3109/10408444.2013.811215
52. Tollefsen, K. E., Scholz, S., Cronin, M. T., Edwards, S. W., de Knecht, J., Crofton, K., Garcia-Reyero, N., Hartung, T., Worth, A., and Patlewicz, G. (2014) Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA) Regul. Toxicol. Pharmacol. 70, 629-640 10.1016/j.yrtph.2014.09.009
53. Balls, M., Combes, R. D., and Bhogal, N. (2012) The use of integrated and intelligent testing strategies in the prediction of toxic hazard and in risk assessment Adv. Exp. Med. Biol. 745, 221-253 10.1007/978-1-4614-3055-1-13
54. Aptula, A. O. and Roberts, D. W. (2006) Mechanistic applicability domains for nonanimal-based prediction of toxicological end points: general principles and application to reactive toxicity Chem. Res. Toxicol. 19, 1097-1105 10.1021/tx0601004
55. Lin, C., Ballinger, K. R., and Khetani, S. R. (2015) The application of engineered liver tissues for novel drug discovery Expert Opin. Drug Discovery 10, 519-540 10.1517/17460441.2015.1032241
56. Strähle, U., Scholz, S., Geisler, R., Greiner, P., Hollert, H., Rastegar, S., Schumacher, A., Selderslaghs, I., Weiss, C., Witters, H., and Braunbeck, T. (2012) Zebrafish embryos as an alternative to animal experiments: a commentary on the definition of the onset of protected life stages in animal welfare regulations Reprod. Toxicol. 33, 128-132 10.1016/j.reprotox.2011.06.121
57. Ozer, J., Ratner, M., Shaw, M., Bailey, W., and Schomaker, S. (2008) The current state of serum biomarkers of hepatotoxicity Toxicology 245, 194-205 10.1016/j.tox.2007.11.021
58. Laverty, H. G., Antoine, D. J., Benson, C., Chaponda, M., Williams, D., and Park, B. K. (2010) The potential of cytokines as safety biomarkers for drug-induced liver injury Eur. J. Clin. Pharmacol. 66, 961-976 10.1007/s00228-010-0862-x
59. Burden, N., Sewell, F., Andersen, M. E., Boobis, A., Chipman, J. K., Cronin, M. T. D., Hutchinson, T. H., Kimber, I., and Whelan, M. (2015) Adverse outcome pathways can drive non-animal approaches for safety assessment J. Appl. Toxicol. n/a 10.1002/jat.3165
60. OECD (2013) Proposal for a Template and Guidance on Developing and Assessing the Completeness of Adverse Outcome Pathways. Series on Testing and Assessment, OECD Publications Office: Paris-France; Vol. 184, pp 1-45.
61. Andersen, M. E., Clewell, R., and Bhattacharya, S. (2012) Developing in Vitro Tools Sufficient by Themselves for 21st Century Risk Assessment, in Towards the Replacement of in Vivo Repeated Dose Systemic Toxicity Testing (Gocht, T. and Schwarz, M., Eds.) Vol. 2, pp 347-360, Imprimerie Mouzet, France.
62. http://caat.jhsph.edu/ (consulted June 2015).
63. http://www.seurat-1.eu/ (consulted June 2015).
64. Vinken, M., Pauwels, M., Ates, G., Vivier, M., Vanhaecke, T., and Rogiers, V. (2012) Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients Arch. Toxicol. 86, 405-412 10.1007/s00204-011-0769-z